CYTH

Rafael Holdings Reports Second Quarter Fiscal 2024 Financial Results

Retrieved on: 
Wednesday, March 13, 2024
Drug development, Patient, CYTH, Niemann–Pick disease, Research, Investment, RFL

NEWARK, N.J., March 13, 2024 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE: RFL), today reported its financial results for the second quarter of fiscal 2024 – and the six months ended January 31, 2024.

Key Points: 
  • NEWARK, N.J., March 13, 2024 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE: RFL), today reported its financial results for the second quarter of fiscal 2024 – and the six months ended January 31, 2024.
  • John will be an integral member of our team, as we advance our existing assets and evaluate additional opportunities for investment,” said Bill Conkling, CEO of Rafael Holdings.
  • During the second quarter of 2024, we increased our investment in Day Three Labs and now hold a majority interest in the company with 79% of the shares outstanding and began consolidating its financial results in the second quarter of 2024.
  • During the second quarter of 2024, we increased our investment in Day Three Labs and now hold a majority interest in the company with 79% of the shares outstanding and we began reporting consolidated its financial results in January 2024.

Cyclo Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update

Retrieved on: 
Monday, March 18, 2024
Biotechnology, Pharmaceutical, Health, Clinical Trials, Research, Exercise, Science, Patent, Alzheimer's disease, Patient, NPC, Therapy, CYTH, FDA, Cyclo, Pharmaceutical industry

Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today reported its financial results for the full year 2023 and provided a business update.

Key Points: 
  • Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today reported its financial results for the full year 2023 and provided a business update.
  • “Following the completion of the merger with Applied Molecular Transport, we are poised to continue building momentum and achieving the value-driving milestones ahead.
  • Net loss for the year ended December 31, 2023 was approximately $20.1 million.
  • The changes in research and development expenses resulted from the increased activity in the Company’s Phase 3 study of Trappsol® Cyclo™ for the treatment of NPC.

Cyclo Therapeutics Announces Issuance of U.S. Patent Covering the Use of Trappsol® Cyclo™ for the Treatment of Alzheimer’s Disease

Retrieved on: 
Thursday, March 14, 2024
Mental Health, Health, Neurology, Clinical Trials, Pharmaceutical, Biotechnology, Science, Patent, Patient, Trial of the century, Therapy, CYTH, Physician, Pharmaceutical industry

Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today announced the United States Patent and Trademark Office (USPTO) has granted U.S. Patent No.

Key Points: 
  • Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today announced the United States Patent and Trademark Office (USPTO) has granted U.S. Patent No.
  • 11,925,659 titled, “Methods for Treating Alzheimer’s Disease,” with claims that cover the use of Trappsol® Cyclo™ for the prevention and treatment of early onset Alzheimer’s disease.
  • “There continues to be a significant unmet need for therapeutic solutions to treat early onset Alzheimer’s disease.
  • We are pleased to add this now issued patent and remain committed to bolstering our patent estate covering Trappsol® Cyclo™,” commented N. Scott Fine, Chief Executive Officer of Cyclo Therapeutics.

Cyclo Therapeutics Announces Allowance of Patent Application for Treatment of Alzheimer’s Disease from the U.S. Patent and Trademark Office

Retrieved on: 
Monday, January 29, 2024
Health, Other Science, Clinical Trials, Pharmaceutical, Science, Biotechnology, CYTH, Patent, Patient, Therapy, Pharmaceutical industry

Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today announced that the Company received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) regarding Cyclo Therapeutics’ U.S. Patent Application No.

Key Points: 
  • Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today announced that the Company received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) regarding Cyclo Therapeutics’ U.S. Patent Application No.
  • 17/289,137 titled, “Methods for Treating Alzheimer’s Disease.”
    N. Scott Fine, CEO of Cyclo Therapeutics, commented, “This patent application allowance represents an important milestone for our Alzheimer’s disease asset as well as a valuable component of our patent estate.
  • With the desperate need for innovation and therapeutic solutions to treat early onset Alzheimer’s disease, we remain hopeful in the potential for Cyclo Therapeutics’ Trappsol® Cyclo™ to play a significant role in the treatment armamentarium.”

Rafael Holdings Reports First Quarter Fiscal 2024 Financial Results

Retrieved on: 
Thursday, December 14, 2023
Research, Investment, Patient, Laboratory, CYTH, RFL, Niemann–Pick disease

NEWARK, N.J., Dec. 14, 2023 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE: RFL) today reported its financial results for the first quarter of fiscal 2024 - the three months ended October 31, 2023.

Key Points: 
  • NEWARK, N.J., Dec. 14, 2023 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE: RFL) today reported its financial results for the first quarter of fiscal 2024 - the three months ended October 31, 2023.
  • “During fiscal 2024, we will continue to focus on advancing our existing portfolio and identifying strategic investments in companies which have the potential to generate value for our stockholders.
  • We believe our strong balance sheet affords us the opportunity to potentially capitalize on attractive investments,” said Bill Conkling, CEO of Rafael Holdings.
  • The year over year reduction in spending is due to the winding down of early-stage programs, including at Barer Institute.

Cyclo Therapeutics, Inc. Completes Merger with Applied Molecular Transport Inc.

Retrieved on: 
Wednesday, December 27, 2023
Biotechnology, Neurology, Health, Pharmaceutical, Clinical Trials, DSM-IV codes, NPC, CYTH, FDA, AMT, NPC1, Therapy, AMTI, Pharmaceutical industry

The combined company will now operate under the name “Cyclo Therapeutics, Inc.” and will continue trading on The Nasdaq Capital Market under the ticker symbol “CYTH”.

Key Points: 
  • The combined company will now operate under the name “Cyclo Therapeutics, Inc.” and will continue trading on The Nasdaq Capital Market under the ticker symbol “CYTH”.
  • Cyclo Therapeutics’ primary focus will continue to be on advancing its pivotal Phase 3 global study (TransportNPC™) evaluating Trappsol® Cyclo™ for Niemann-Pick Disease Type C1 (NPC1).
  • “The completion of this merger with Applied Molecular Transport represents a significant milestone and bolsters our confidence and excitement for the future of Cyclo Therapeutics.
  • With the merger now closed and following our recent positive Type C meeting with the FDA, fundamentally the Company has never been stronger,” commented N. Scott Fine, CEO of Cyclo Therapeutics.

Cyclo Therapeutics Announces Positive Outcome from Type C Meeting with the U.S. FDA Discussing Trappsol® Cyclo™ Clinical Program for the Treatment of Niemann-Pick Disease Type C1

Retrieved on: 
Monday, December 18, 2023
Health, FDA, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Lung, Brain, Safety, Spleen, Senior, Business development, Food, Therapy, NPC1, Liver, Priority review, NPC, Patient, CYTH, Trial of the century, DSM-IV codes, Standard of care, Cyclo, SOC, Cell, Pharmaceutical industry

N. Scott Fine, Chief Executive Officer of Cyclo Therapeutics, added, “We view our Type C meeting with FDA as a catalytic and transformational milestone for our ongoing pivotal Phase 3 NPC program.

Key Points: 
  • N. Scott Fine, Chief Executive Officer of Cyclo Therapeutics, added, “We view our Type C meeting with FDA as a catalytic and transformational milestone for our ongoing pivotal Phase 3 NPC program.
  • For more information about the Company’s TransportNPC™ pivotal Phase 3 study, visit www.ClinicalTrials.gov and reference identifier NCT04860960 .
  • Cyclo Therapeutics received Orphan Drug Designation for Trappsol® Cyclo™ to treat NPC1 in both the U.S. and EU and Fast Track and Rare Pediatric Disease Designations in the U.S.
  • The Rare Pediatric Disease Designation is one of the chief requirements for sponsors to receive a Priority Review Voucher in the U.S. upon marketing authorization.

APPLIED MOLECULAR INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Applied Molecular Transport Inc. - AMTI

Retrieved on: 
Tuesday, November 28, 2023
Class Action Lawsuit, Professional Services, Legal, Sale, AMTI, KSF, CYTH, Cyclos

and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Applied Molecular Transport Inc. (NasdaqCM: AMTI) to Cyclo Therapeutics, Inc. (NasdaqCM: CYTH).

Key Points: 
  • and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Applied Molecular Transport Inc. (NasdaqCM: AMTI) to Cyclo Therapeutics, Inc. (NasdaqCM: CYTH).
  • Under the terms of the proposed transaction, shareholders of Applied Molecular will receive 0.174 shares of Cyclo for each share of Applied Molecular that they own.
  • KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.
  • To learn more about KSF, whose partners include the Former Louisiana Attorney General, visit www.ksfcounsel.com .

Cyclo Therapeutics to Present at the 20th Annual WORLDSymposium™ 2024

Retrieved on: 
Tuesday, November 21, 2023
Biotechnology, Health, Science, Pharmaceutical, Research, Therapy, CYTH, DSM-IV codes, Pharmaceutical industry, Limestone

Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company focused on developing transformative therapies for rare and neurological diseases with limited treatment options, today announced its abstract has been accepted for platform presentation at the 20th Annual WORLDSymposium™ being held February 4-9, 2024 in San Diego, CA.

Key Points: 
  • Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company focused on developing transformative therapies for rare and neurological diseases with limited treatment options, today announced its abstract has been accepted for platform presentation at the 20th Annual WORLDSymposium™ being held February 4-9, 2024 in San Diego, CA.
  • Details of the platform presentation are as follows:

Cyclo Therapeutics Reports Third Quarter 2023 Financial Results

Retrieved on: 
Wednesday, November 15, 2023
Biotechnology, Pharmaceutical, Health, Clinical Trials, Balance sheet, Therapy, Exercise, Private placement, NPC, Patient, CYTH, Science, AMTI, Cyclo, Pharmaceutical industry, Security (finance)

Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today reported its financial results for the third quarter 2023.

Key Points: 
  • Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today reported its financial results for the third quarter 2023.
  • “Our number one priority remains to be the solid operational execution of our TransportNPC™ study.
  • We remain hopeful that we will bring enrollment for this important study to a close in the coming months,” commented N. Scott Fine, Chief Executive Officer of Cyclo Therapeutics.
  • “Further, during the quarter we entered into a strategic merger agreement with Applied Molecular Transport, which we expect to close before year end.